VAD方案和PCD方案治疗多发性骨髓瘤的效果临床效果刍议

The Clinical Effect of VAD and PCD in the Treatment of Multiple Myeloma

目的探究将VAD方案和PCD方案应用于多发性骨髓瘤患者治疗中的效果,评价其临床应用意义。方法在该院数据库中调取时间段2017年1月—2018年1月间收入的所有多发性骨髓瘤患者的一般资料;根据该次实验要求,抽取出其中30例患者开展研究,并将其分为两组,分别命名为对照组(n=15)与实验组(n=15)。对照组患者采用方案进行治疗,实验组患者则应用PCD方案进行治疗,治疗完成后评价患者的骨髓瘤客观缓解率以及治疗期间所发生的毒副反应评价治疗效果。结果实验结果显示,实验组患者在治疗后,其客观缓解率可达66.67%(10/15),其数据明显高于对照组患者的客观缓解率20.00%(3/15),组间对比差异有统计学意义(χ~2=44.349 8,P<0.05);并且实验结果中显示实验组患者的神经毒性、血细胞减少以及腹胀等毒副反应数据对比差异无统计学意义(P>0.05)。结论将PCD应用于多发性骨髓瘤患者的治疗中,能够有效改善患者的治疗效果,使患者的病情得到缓解,除此之外这种治疗方案用药安全性较高,不会对患者造成额外的毒副反应,具有高度的应用价值,值得推广使用。

Objective To investigate the effect of VAD and PCD in the treatment of patients with multiple myeloma and evaluate its clinical significance.Methods General data on all patients with multiple myeloma who had income from January 2017 to January 2018 were collected from our database;according to the requirements of this experiment,30 patients were selected for research and they were divided into two groups:the control group(n=15)and experimental group(n=15).The patients in the control group were treated with the protocol.The patients in the experimental group were treated with the PCD regimen.After the treatment was completed,the objective response rate of the patients with myeloma and the toxic side effects during the treatment were evaluated.Results The experimental results showed that the objective response rate of the experimental group was 66.67%(10/15)after treatment,and the data was significantly higher than the objective response rate of the control group 20.00%(3/15).The difference was statistically significant(χ^2=44.349 8,P<0.05);and the experimental results showed that there was no statistically significant difference in the data of neurotoxicity,cytopenia and abdominal distension in the experimental group(P>0.05).Conclusion The application of PCD in the treatment of patients with multiple myeloma can effectively improve the patient's therapeutic effect and alleviate the patient's condition.In addition,this treatment is safer and will not cause additional disease to the patient.The toxic side reaction has a high application value and is worthy of promotion.